Knowledge Management System of Kunming Institute of Botany,CAS
| Platelet-activating factor acetyl hydrolase IB2 dysregulated cell proliferation in ovarian cancer | |
| He,YingYing; He,Zhicheng; Zhang,Xiaoyu; Liu,Shubai | |
| 2021 | |
| Source Publication | CANCER CELL INTERNATIONAL
 |
| ISSN | 1475-2867 |
| Volume | 21Issue:1Pages:697 |
| Abstract | Background Ovarian cancer is the leading cause of death from gynaecologic illnessed worldwide. Platelet-activating factor acetyl hydrolase IB2 (PAF-AH IB2) is an intracellular serine esterase that hydrolyzes platelet-activating factor, a G-protein-like trimer with two catalytic subunits and one regulatory subunit. The regulatory role of PAF-AH IB2 in the oncogenesis of ovarian cancer is not well understood. Methods In this study, the TCGA dataset and clinical cancer tissue microarray were utilized to investigate abnormal overexpression of PAF-AH IB2 in ovarian cancer. To investigate the impact on the cell proliferation, migration, and tumorigenicity in vitro, PAF-AH IB2 stable knocking down (KD) ovarian cancer cells were established by ShRNA. The whole transcription profiling, tyrosine kinase profiling and standard cell functional assays were integrated to explore the biological importance and mechanism of PAF-AH IB2 modulated in ovarian cancer. Results PAF-AH IB2 was identified significantly overexpression in four subtypes of ovarian cancer. In vitro, PAF-AH IB2 KD significantly inhibited cancer cell proliferation, migration, and tumorigenicity, activated caspases and caused cell cycle arrest, and made the cells more sensitive to PAF. PAF-AH 1B2 KD cells down-regulated several key regulators of the multiple tyrosine kinases-mediated signaling pathway, suggesting a novel interaction network between the growth factor receptors pathway and PAF-AH 1B2 mediated PAF signalling. Conclusions These findings revealed a previously undiscovered role for PAF-AH IB2 as a potenial therapy target and essential signaling mediators in ovarian cancer pathogenesis, as well as new possible preventive and therapeutic strategies to inhibit this enzyme in clinical treatment for ovarian cancer. |
| Keyword | Ovarian cancer Ester lipid Tyrosine kinase signaling pathway Platelet-activating factor FACTOR-ACETYLHYDROLASE ACTIVITY LYSOPHOSPHATIDIC ACID FACTOR RECEPTOR EMERGING ROLE EXPRESSION GROWTH PAF MECHANISMS PAFAH1B3 SUBUNIT |
| DOI | 10.1186/s12935-021-02406-9 |
| WOS ID | WOS:000732980900009 |
| Citation statistics | |
| Document Type | 期刊论文 |
| Identifier | http://ir.kib.ac.cn/handle/151853/73457 |
| Collection | 中国科学院昆明植物研究所 |
| Affiliation | 1.Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, 132 Lanhei Rd, Kunming 650201, Yunnan, Peoples R China 2.Yunnan Univ, Sch Chem Sci & Technol, Kunming 650091, Yunnan, Peoples R China 3.Univ Chinese Acad Sci, Beijing 100049, Peoples R China |
| Recommended Citation GB/T 7714 | He,YingYing,He,Zhicheng,Zhang,Xiaoyu,et al. Platelet-activating factor acetyl hydrolase IB2 dysregulated cell proliferation in ovarian cancer[J]. CANCER CELL INTERNATIONAL,2021,21(1):697. |
| APA | He,YingYing,He,Zhicheng,Zhang,Xiaoyu,&Liu,Shubai.(2021).Platelet-activating factor acetyl hydrolase IB2 dysregulated cell proliferation in ovarian cancer.CANCER CELL INTERNATIONAL,21(1),697. |
| MLA | He,YingYing,et al."Platelet-activating factor acetyl hydrolase IB2 dysregulated cell proliferation in ovarian cancer".CANCER CELL INTERNATIONAL 21.1(2021):697. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment